
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is currently facing near-term risks related to clinical results for its lead ADC candidates, with potential downward adjustments in market penetration, higher discount rates, and longer time horizons to approval. However, the company's differentiated safety profile for its lead asset, STRO-004, as well as its strong pipeline of other potential treatments for a variety of tumor types, indicate long-term potential for significant earnings and revenue growth. With this in mind, a strong financial outlook and a discounted cash flow analysis, we have increased our price target for Sutro Biopharma to $50.
Bears say
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company with a negative outlook due to its early stage in the development process and potential regulatory and commercial risks. The company's promising drug candidate STRO-004 has shown encouraging early data but is still in dose optimization and has yet to demonstrate significant levels of efficacy or safety through clinical trials. Despite a strong financial position, the company may require additional equity financing and faces intense competition in the cancer therapeutic industry. The stock's current weaker valuation creates a potentially more attractive entry point, but it remains a high-risk investment.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares